[ad_1]
The lead drug, Sun Pharmaceutical Industries, said today that it has received approval from the US Health Regulator for its injection of INFUGEM used for the treatment of cancer. This is the first approval of the US Food and Drug Administration (USFDA) for a Halol factory product after the receipt of the Institutional Inspection Report (IRE) in June 2018, Sun Pharma said in a statement
. for the injection of INFUGEM (gemcitabine in 0.9% sodium chloride injection) 10 mg / mL, for intravenous use in a bag ready to administer, it has added.
Sun Pharma, CEO of North America, Abhay Gandhi said, We are excited to add this new product to our expanding oncology portfolio, as gemcitabine is one of the cytotoxic most commonly used in oncology. "
The technology used to formulate INFUGEM eliminates the risks badociated with It added that, according to IQVIA," the size of the addressable market is about $ 35 million for the 12 months ending in March 2018 " , he added.Pharma stated:
INFUGEM uses a patented technology that can pre-mix cytotoxic products in oncology in a sterile environment and provide them to prescribers in RTA infusion bags. 19659002] The shares of Sun Pharmaceutical Industries are trading today at 550.05 Rs per scrip on BSE, up 0.23% from its previous closing.
[ad_2]
Source link
